NCT04276545View on ClinicalTrials.gov

Dexmedetomidine Improves the Surgical Field and Postoperative Recovery of Nasal Endoscopic Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 10, 2020

Study Completion Date

March 10, 2020

Conditions
DexmedetomidineBleedingSurgical Field
Interventions
DRUG

IV administration of DEX to investigate the effects for functional nasal endoscopic surgery

IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.

DRUG

IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery

IV administration of midazolam (0.05mg/kg) after induction.

Trial Locations (1)

200031

Eye, Ear, Nose and Throat Hospital, Shanghai

All Listed Sponsors
lead

Eye & ENT Hospital of Fudan University

OTHER

NCT04276545 - Dexmedetomidine Improves the Surgical Field and Postoperative Recovery of Nasal Endoscopic Surgery | Biotech Hunter | Biotech Hunter